Stock research
TSHA Taysha Gene Therapies, Inc.
Healthcare • Biotechnology
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases...…
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
3M change
-7.45%
Range high
$6.98
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in TSHA?
Price
Showing 3M history. Source: FMP historical price full.
- Prev Close
- $6.20
- Day High
- $6.47
- Day Low
- $6.20
- 52w High
- $7.30
- 52w Low
- $2.63
- Volume
- 1,905,720
- Avg Volume
- Beta
- 1.155
* TTM/most recent where available
Company
- Ticker
- TSHA
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Sean Nolan
- Employees
- 99
- Website
- www.tayshagtx.com
Key Metrics
- Market Cap
- 2.07B
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).